期刊文献+

硼替佐米增加HL-60细胞对TRAIL的敏感性 被引量:1

Effect of Bortezomib on Sensitization of HL-60 Cells to TRAIL
下载PDF
导出
摘要 本研究旨在探讨硼替佐米(bortezomib)是否可以增加HL-60细胞对肿瘤坏死因子相关凋亡诱导配体(TNF-related apoptosis-inducing ligand,TRAIL)的敏感性及其可能的作用机制。选择亚细胞毒浓度的硼替佐米与不同浓度的TRAIL联合处理HL-60细胞,用MTT法检测并绘制增殖抑制曲线,用Annexin V/PI双染色流式细胞术检测细胞凋亡,Western blot检测caspase-8的表达。结果表明,亚细胞毒浓度的硼替佐米与10ng/ml的TRAIL联合作用于HL-60细胞时细胞凋亡率较单独应用TRAIL时增加,相应的caspase-8的表达也随之增加。结论:亚细胞毒浓度的硼替佐米可以增加HL-60细胞对TRAIL的敏感性,其机制可能与促进caspase-8表达有关。 This study was aimed to explore whether bortezomib can sensitize HL-60 cells to TNF-related apoptosisinducing ligand (TRAIL) and to investigate its possible mechanism. The HL-60 cells were treated by different concentrations of TRAIL combined with subtoxic concentration of bortezomib. The proliferative inhibition of treated HL-60 cell was analysed by MTT assay. The cell apoptosis was determined by flow cytometry with Annexin V/PI double staining and the expression of caspase-8 was detected by Western blot. The results showed that the subtoxic concentration of bortezomib combined with l0 ng/ml of TRAIL enhanced apoptosis of HL-60 cells, as compared with TRAIL used alone; the expression of caspase-8 increased correspondingly. It is concluded that subtoxic concentration of bortezomib can sensitize HL-60 cells to TRAIL and its mechanism may be related to upregulation of caspase-8 expression.
出处 《中国实验血液学杂志》 CAS CSCD 2010年第3期617-620,共4页 Journal of Experimental Hematology
关键词 硼替佐米 肿瘤坏死因子相关凋亡诱导配体 白血病 细胞凋亡 bortezomib TRAIL leukemia apoptosis
  • 相关文献

参考文献10

  • 1Zhang XD, Nguyen T, Thomas WD, et al. Mechanisms of resistance of normal ceils to TRAIL induced apoptosis vary between different cell types. FEBS Lett, 2000 ;482 (3) : 193 - 199.
  • 2Khanbolooki S, Nawrocki ST, Arumugam T, et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther, 2006 ;5 ( 9 ) : 2251 - 2260.
  • 3Klener P Jr, Leahomschi S, Molinsky J, et al. TRAIL-induced apoptosis of HL60 leukemia ceils: two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFalpha but not to idarubicin and cytarabine. Blood Ceils Mol Dis, 2009 ;42( 1 ) :77 - 84.
  • 4孙启鑫,孟凡义,扶云碧,李利.硼替佐米单用或联合三尖杉酯碱体外诱导HL-60细胞凋亡实验研究[J].中国实验血液学杂志,2007,15(2):233-236. 被引量:15
  • 5Fox NL, Humphreys R, Luster TA, et al. Tumor necrosis factor- related apoptosis-indueing ligand (TRAIL) receptor-1 and receptor- 2 agonists for cancer therapy. Expert Opin Biol Ther, 2009 ; [ Epub ahead of print].
  • 6Sayers TJ, Brooks AD, Koh CY, et al. The proteasome inhibitor PS-341 sensitize neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood, 2003 ; 102 ( 1 ) :303 - 310.
  • 7Copeland KA, Sherman SN, Kendeigh CA, et al. Flip flops, dress clothes, and no coat: clothing barriers to children's physical activity in child-care centers identified from a qualitative study. Int J Behav Nutr Phys Act, 2009 ;6:74.
  • 8Brooks AD, Sayers TJ. Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis. Cancer Immunol Immunother, 2005;54(5) :499 - 505.
  • 9Panner A, Crane CA, Weng C, et al. A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res, 2009 ; 69 ( 20 ) : 7911 - 7916.
  • 10White-Gilbertson SJ, Kasman L, McKillop J, et al. Oxidative stress sensitizes bladder cancer ceils to TRAIL mediated apoptosis by down-regtdating anti-apoptotic proteins. J Urol, 2009;182 (3) : 1178 - 1185.

二级参考文献11

  • 1Boccadoro M,Morgan G,Cavenagh J.Preclinical evaluation of the proteasome inhibitor bortezomib in cancer.Cancer Cell Int,2005;5:18-27
  • 2D.L.斯佩克特著(黄培堂等译).细胞实验指南.北京:科学出版社.2001:108-109
  • 3Voorhees PM,Dees EC,ONeil B,et al.The proteasome as a target for cancer therapy.Clin Cancer Res,2003; 9:6316-6325
  • 4Gatto S,Scappini B,Pham L,et al.The proteasome inhibitor PS341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.Haematologica,2003; 88:853-863
  • 5Horton TM,Gannavarapu A,Blaney SM,et al.Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.Cancer Chemother Pharmacol,2006; 58:13-23
  • 6Dai Y,Rahmani M,Pei XY,et al.Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.Blood,2004; 104:509-518
  • 7Dai Y,Rahmani M,Grant S,et al.Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK-and NF-kappaB-dependent process.Oncogene,2003; 22:7108-7122
  • 8Smolewski P,Duechler M,Linke A,et al.Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells.Leuk Res,2006; 30:1521-1529
  • 9Cortes J,Thomas D,Koller C,et al.Phase I study of bortezomib in refractory or relapsed acute leukemias.Clin Cancer Res,2004; 10:3371-3376
  • 10Tallman MS.New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents.Hematology Am Soc Hematol Educ Program,2005:143-150

共引文献14

同被引文献8

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部